Covid-19: Contributions from Psychopharmacology

The COVID-19 pandemic is causing a major burden on personal health, healthcare systems and the global economy. For the last two years the COVID-19 pandemic has dramatically changed our lives in many personal and professional areas. For millions of us, due to infection rates, but also to protection measures such as lockdowns the corona pandemic has significantly changed the way we work, how we live, and how we interact with technology. In addition to the development of effective vaccines, anti-viral and anti-inflammation strategies are of eminent importance to treat people with acute infection or at least prevent serious negative outcomes. In contrast to the fast development of several effective vaccines that were remarkably available already after one year of the pandemic, novel effective anti-viral compounds are still in development. The only currently used effective medications against severe SARS-CoV-2 virus infection are corticosteroids [1].

Publication History

Article published online:
25 January 2022

• References

• 1 Mueller JK, Riederer P, Mueller WE. Neuropsychiatric drugs against COVID-19: What is the clinical evidence?. Pharmacopsychiatry 2022; 55: 7-15 DOI: 10.1055/a-1717-2381.
• 2 Murru A, Manchia M, Hajek T. et al. for the International Group for The Study of Lithium Treated Patients (IGSLi) Lithium's Antiviral Effects: A Potential Drug for CoViD-19 Disease?. Int J Bipolar Disord 2020; 8: 21 DOI: 10.1186/s40345-020-00191-4.
• 3 Liu X, Verma A, Garcia G. et al. Targeting the coronavirus nucleocapsid protein through GSK-3 inhibition. Proc Natl Acad Sci USA. 2021; 118: e2113401118 DOI: 10.1073/pnas.2113401118.
• 4 Khosravi M. Candidate Psychotropics against SARS-CoV-2: A Narrative Review. Pharmacopsychiatry 2022; 55: 16-23 DOI: 10.1055/a-1551-3756.
• 5 Nykamp MJ, Zorumski CF, Reiersen AM. et al. Opportunities for Drug Repurposing of Serotonin Reuptake Inhibitors: Potential Uses in Inflammation, Infection, Cancer, Neuroprotection, and Alzheimer's Disease Prevention. Pharmacopsychiatry 2022; 55: 24-29 DOI: 10.1055/a-1686-9620.
• 6 Bonnet U, Juckel G, Scherbaum N. et al. Are Persons Treated with Antidepressants and/or Antipsychotics Possibly Better Protected against Severe COVID 19?. Pharmacopsychiatry 2021; 54: 142-143
• 7 Bonnet U, Claus B, Schaefer M. et al. Impact of Psychiatric and Related Somatic Medications on the Duration and Severity of COVID-19: A Retrospective Explorative Multi-center Study from the German Metropolitan Ruhr-area. Pharmacopsychiatry 2022; 55: 30-39 DOI: 10.1055/a-1559-3904.
• 8 Plasencia-García BO, Rico-Rangel MI, Rodríguez-Menéndez G. et al. Drug-drug Interactions between COVID-19 Treatments and Antidepressants, Mood Stabilizers/Anticonvulsants, and Benzodiazepines: Integrated Evidence from 3 Databases. Pharmacopsychiatry 2022; 55: 40-47 DOI: 10.1055/a-1492-3293.
• 9 Veerman SRT, Bogers JPAM, Cohen D. et al. COVID-19: Risks, Complications, and Monitoring in Patients on Clozapine. Pharmacopsychiatry 2022; 55: 48-56 DOI: 10.1055/a-1562-2521.